Skip to main content

Table 3 Comparison of risk of antituberculosis-drug induced liver injury (antiTB-DILI) between two treatment groups: Intention-to-treat approach

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

 

Placebo

Silymarin

p-value

RR

RD

NNT

(N = 28)

(N = 27)

(95 % CI)

DILI

9 (32.1)

1 (3.7)

0.012

0.12 (0.02, 0.85)

0.28 (0.10, 0.47)

3.50 (2.11, 2.37)

Non-DILI

19 (67.9)

26 (96.3)

 

1

  
  1. DILI, drug induced liver injury; RR, risk ratio; RD, risk difference; NNT, number need to treat
  2. Categorical variables reported as N (%)
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us